Company intelligence / Profile preview

Xue

Guangzhou, Guangdong, China

Ownership: Private
Employees: ~4500
Development stage: Other

Overview

Xiangxue Pharmaceutical is a major Chinese pharmaceutical manufacturer with robust R&D, more than 150 commercialized products, active TCR-T and cell therapy programs (highest phase: Phase 2), and strong growth in both traditional Chinese medicine and novel biotherapeutics

Therapeutic areas: CardiovascularInfectious DiseasesRare DiseasesOtherOncology
Modalities: Small moleculeTCR-T cell therapyCell therapyTraditional Chinese Medicine (TCM)Monoclonal antibody (for oncology pipeline)
Industry: Biotech

Partnerships

Athenex (cancer therapy development)WuXi Biologics (rare disease and biologics co-development)

Beyond the preview

Go deeper on Xue.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xue.

Explore the full profile